Your account is not claimed yet. You can sign up with ORCID to claim your account.

Arie Regev

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Venues

Alimentary pharmacology & therapeutics

Drug safety

Indiana University Health

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Indiana University Health Jan 1o 2008

United States

Associate Professor of Medicine :: Medicine, Division of Gastroenterology and Hepatology

Publications

Melissa Palmer, David E Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I Avigan, Arie Regev, Paul H Hayashi, James H Lewis, Ruby Mehta, Stephen A Harrison, Massimo Siciliano, Charles A McWherter, Raj K Vuppalanchi, Cynthia Behling, Veronica Miller, Naga P Chalasani, Arun J Sanyal
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Alimentary pharmacology & therapeutics (2023)
Lauren Pavlik, Arie Regev, Paul A Ardayfio, Naga P Chalasani
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Drug safety 42 (6) (2020)
Arie Regev, Melissa Palmer, Mark I Avigan, Lara Dimick-Santos, William R Treem, John F Marcinak, Daniel Seekins, Gopal Krishna, Frank A Anania, James W Freston, James H Lewis, Arun J Sanyal, Naga Chalasani
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Alimentary pharmacology & therapeutics 49 (6) (2019)
Melissa Palmer, Arie Regev, Keith Lindor, Mark I Avigan, Lara Dimick-Santos, William Treem, John F Marcinak, James H Lewis, Frank A Anania, Daniel Seekins, Benjamin L Shneider, Naga Chalasani
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Alimentary pharmacology & therapeutics 51 (1) (2019)

Arie Regev.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Arie Regev